A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work ...
In the AI era, thriving life sciences organizations will differentiate themselves based on their ability to combine AIs power ...
Congress finally reauthorized the Rare Pediatric Disease Priority Review Voucher program, after it expired in 2024. That matters a lot to patients and drug developers, writes George Magrath, M.D.
On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, following ...
The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...
Advances in oligonucleotide therapeutics demand synthesis tools that can scale efficiently while maintaining high product quality. Explore how next‑generation primer supports can improve process ...
There is more than one way to blockbuster product sales, and sometimes smaller might be better, writes Bennett Smith.
On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through ...
On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled ...
The “Bring your authentic self to work” mantra echoes incessantly around the corporate world. Everyone from executive coaches to New York Times bestselling books is saying that ‘authenticity’ is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results